Skip to Content

Acacia Pharma Group PLC ACPH

Rating as of

Morningstar’s Analysis

Valuation
Currency in EUR
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Acacia Pharma Group PLC is a pharmaceutical company, focused on the development and commercialization of hospital products for U.S and international markets to treat and prevent nausea and vomiting suffered by surgical and cancer patients. Its operating segment includes the development and commercialization of intellectual property through direct sale of the protected products.

Contact
Royston Road, The Officers’ Mess
Cambridge, CB22 4QH, United Kingdom
T +44 1223919760
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Dec 31, 2018
Fiscal Year End Dec 31, 2019
Stock Type
Employees 37